Stewart immediately broke at the reference, bursting into laughter as he jumped out of his chair and took a few steps around ...

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased ...

Four Goldman Sachs stock picks make sense for growth and income investors charting a course for the rest of what could be a ...

JAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and cancers added to its label in 2019. Now, a study designed to prove its safety ...

Products with patents expiring between 2025 and 2027 are Prevnar, Ibrance, Eliquis, Xeljanz, Xtandi, and Inlyta. All these products generated around $26 billion in sales during FY2024, which is a ...

Pfizer has received approval from the US FDA for its rheumatoid arthritis (RA) drug, Xeljanz, which is the first approved RA treatment in a new class of medicines known as Janus kinase inhibitors ...

However, sales of some key drugs like Prevnar, Xeljanz and Ibrance and new RSV vaccine, Abrysvo declined in the quarter. Seagen drugs contributed $915 million to the top line in the fourth quarter ...

John Kenney Jr., MD, Lifetime Achievement Award and Lectureship recipient Pearl E. Grimes, MD, FAAD, delivered a tribute to her predecessor as she discussed the history and advancements of vitiligo.